Unlocking Oral Bioavailability: How SNAC Is Transforming Drug Delivery of Biologics

The FDA approval of an oral semaglutide (Rybelsus^®) marked a turning point for oral bioavailability, not just type 2 diabetes, but for oral therapeutics more broadly. Traditionally, biologics and large macromolecules such as peptides and proteins face significant challenges in gastrointestinal (GI) absorption. These drugs are prone to degradation in the stomach’s acidic environment and are often blocked by mucosal barriers or tight junctions in the epithelium.

As a result, parenteral administration (via injection) has been the standard route for effective systemic absorption. However, frequent injections can cause patient discomfort, inconvenience, and non-adherence, especially for chronic conditions.

At LGM Pharma, we support drug developers with sourcing solutions for innovative and niche drug substances and enhancer molecules. One such compound is salcaprozate sodium (SNAC), a clinically validated oral absorption enhancer that improves oral bioavailability, enables the successful approval of oral semaglutide, and is redefining the delivery of biologics.

Key Takeaways

• Salcaprozate sodium (SNAC) is a clinically validated oral absorption enhancer, and the same excipient technology behind Rybelsus®, the FDA-approved oral formulation of semaglutide, making it the first proven commercial pathway for turning an injectable biologic into a pill.
• Biologics and large macromolecules like peptides and proteins typically achieve less than 1% oral bioavailability on their own, since they’re degraded by stomach acid, broken down by digestive enzymes, and blocked by the tight junctions of the intestinal lining.
• SNAC addresses all three of these barriers at once: it raises local pH to protect against acidic degradation, inhibits the enzyme pepsin to prevent enzymatic breakdown, and increases cell membrane fluidity to improve transcellular permeability.
• Unlike many other absorption enhancers, SNAC has FDA Generally Recognized As Safe (GRAS) status, doesn’t require complex enteric coatings (which can cause inconsistent absorption between patients), and avoids mucoadhesive formulations that lose effectiveness as mucus naturally turns over.
• SNAC is compatible with standard, already-established manufacturing processes and common oral dosage forms; including tablets, capsules, and softgels. Unlike more complex alternative technologies such as nanoparticles or Self-Emulsifying Drug Delivery Systems (SEDDS), which require specialized and costly development.

A Clinically Validated Absorption Enhancer

SNAC addresses multiple barriers to oral absorption, particularly for biologics and macromolecules where oral bioavailability is often less than 1%:

     1. Acidic Degradation:

• • The stomach’s highly acidic environment rapidly degrades unprotected peptides.
  • SNAC increases local pH, creating a protective microenvironment.

     2. Enzymatic Breakdown:

• • Enzymes like pepsin cleave peptide bonds, leading to significant loss of the active pharmaceutical ingredient (API).
  • SNAC inhibits pepsin, preserving drug integrity.

      3. Conformational Instability:

• • pH fluctuations can alter macromolecular structure, rendering it inactive.
  • SNAC stabilizes the drug in its monomeric (active) form.

      4. Physical Barriers:

• • The GI mucosa and tight epithelial junctions restrict paracellular transport of molecules larger than 500 Da.
  • SNAC enhances transcellular permeability by increasing the fluidity of cellular membranes. It also forms non-covalent complexes with APIs and improving membrane diffusion through enhanced lipophilicity.

SNAC’s Unique Advantages for Oral Bioavailability

SNAC is not the only permeation enhancer, but beyond the targeted mechanisms highlighted above, SNAC offers an uncommon combination of additional safety advantages. FDA has granted it Generally Recognized As Safe (GRAS) status, underscoring its safety profile, making it an exceptionally scalable and regulatory-friendly solution for improving oral bioavailability in pharmaceutical development.

SNAC offers localized activity at high concentrations within the GI tract. While systemic exposure is a potential concern with other absorption enhancers, SNAC possesses a well-established and favorable toxicological profile.
SNAC is also more efficacious than many other absorption/permeation enhancers. It does not necessitate complex enteric coating for its function. These coatings can exhibit highly variable intersubject absorption. SNAC also avoids mucoadhesive formulations that are often rendered ineffective by rapid mucus turnover.

Practical SNAC Solutions 

There are alternative formulation techniques for oral delivery like nanoparticles, Hot Melt Extrusion (HME), Solid Lipid Nanoparticles (SLNs), and Self-Emulsifying Drug Delivery Systems (SEDDS). These are complex and expensive, and some still require validation.

By contrast:

• SNAC formulations are manufactured by simple, established, and cost-effective manufacturing processes.
• SNAC is effective, dependable and regulator-friendly, proven through clinical validation and its continued use in the FDA-approved oral semaglutide.
• SNAC can easily be manufactured at large scale through conventional processes.
• SNAC’s flexibility means it is compatible with a variety of established oral dosage forms, including tablets, capsules, and soft gels, allowing for diverse oral bioavailability formulation strategies.
• Studies have shown that SNAC dramatically enhances patient compliance by transforming traditionally injectable drugs into convenient oral doses, improving the overall patient experience.

Sourcing SNAC for Oral Bioavailability

LGM Pharma helps drug developers procure high-quality, hard-to-find drug substances like SNAC with confidence through our pre-approved network of manufacturers.

As a leading supplier of high-purity SNAC for both formulation development and commercial manufacturing, we offer a robust and reliable supply chain supported by:

• A fully validated commercial process: Capable of metric-ton production, ensuring ample supply for diverse manufacturing needs.
• A patented route of synthesis: Non-infringing route of synthesis provides intellectual property protection.
• Readily available: Regular production campaigns guarantee timely access to the material.

The manufacturing process for oral formulations incorporating SNAC is straightforward, well-established, and cost-efficient, enhancing its attractiveness as a practical and scalable solution for pharmaceutical companies.

SNAC represents a pivotal advancement in oral drug delivery. It offers a proven, safe, and scalable solution to overcome the formidable challenges of delivering peptides and proteins orally, thereby unlocking their full therapeutic potential and leading to significantly improved patient outcomes.

Frequently Asked Questions

1. What is SNAC?
   SNAC (salcaprozate sodium) is an oral absorption enhancer that helps biologics and peptides survive digestion and get absorbed into the bloodstream when taken as a pill instead of an injection.
2. Why do biologics normally have such low oral bioavailability?
   Biologics and peptides are large, fragile molecules. Stomach acid degrades them, digestive enzymes like pepsin break them down, and even the ones that survive digestion are usually too large to pass through the tight junctions of the intestinal lining — all of which combine to keep unprotected oral bioavailability under 1%.
3. How does SNAC actually improve oral bioavailability?
   SNAC works on multiple fronts simultaneously: it raises the local pH in the stomach to create a more protective environment, inhibits the enzyme responsible for breaking down peptide bonds, helps stabilize the drug’s active molecular structure, and increases the permeability of intestinal cell membranes so more of the drug can pass through.
4. Is SNAC FDA-approved?
   SNAC holds FDA GRAS (Generally Recognized As Safe) status and is the enhancer technology behind Rybelsus®, the first FDA-approved oral formulation of semaglutide.
5. What dosage forms is SNAC compatible with?
   Tablets, capsules, and softgels — SNAC works with conventional, already-established manufacturing processes rather than requiring specialized or experimental technology.
6. How is SNAC different from other oral absorption enhancers?
   Many alternative enhancer technologies rely on complex enteric coatings, which can produce inconsistent absorption between patients, or mucoadhesive formulations, which lose effectiveness as the body’s mucus layer naturally turns over. SNAC avoids both of these limitations and has already been proven at commercial scale through its use in an approved product.
7. Why does oral bioavailability matter for patients?
   Many biologic therapies currently require frequent injections, which can be uncomfortable, inconvenient, and a barrier to consistent use, especially for chronic conditions. Improving oral bioavailability allows these therapies to be taken as a simple pill instead, which can meaningfully improve how consistently patients stay on their treatment.

Partner with LGM Pharma to source SNAC and other specialized APIs that help bring next-generation therapies to patients faster.